Clinical trials: Pancreatic Ductal Adenocarcinoma (PDAC)
Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages.
- Trial name
- ResCPa (NCT07153289)
- Testing
- CD318-CAR-T cells
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Pancreatic Ductal Adenocarcinoma (PDAC)
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.
- Trial name
- FALCON (NCT07829185)
- Testing
- modified FOLFIRINOX, Pentamidine 300 MG Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Oklahoma
Pancreatic Ductal Adenocarcinoma (PDAC)
OSCAR I STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic…
- Trial name
- NCT06481397
- Testing
- ONCObind (Onco-Seraph) 100 Filter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExThera Medical Corporation
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Metastatic Pancreatic Ductal Adenocarcinoma
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine-Abraxane or Gemcitabine monotherapy
- Trial name
- NALPAC (NCT05472259)
- Testing
- Nanoliposomal irinotecan, 5 FU, Leucovorin
- Where
- 13 sites in Belgium
- Volunteers
- 134 people
- Sponsor
- Belgian Group of Digestive Oncology
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma
- Trial name
- NCT03977233
- Testing
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Pancreatic Cancer Recurrence in the Netherlands
The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, PDAC
- Trial name
- NCT04605237
- Where
- Netherlands
- Volunteers
- 1,750 people
- Sponsor
- UMC Utrecht
Pancreatic Ductal Adenocarcinoma
Effects of Different Methods of PDAC Specimen Acquisition on Primary Cell Culture and Application
The purpose of this study is to investigate the difference in the success rate of culturing primary cells derived from pancreatic ductal adenocarcinoma specimens of patients which obtained by endoscopic ultrasound-guided…
- Trial name
- NCT04797676
- Testing
- different methods of specimen acquisition
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Pancreatic Ductal Adenocarcinoma (PDAC)
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
To evaluate the safety and efficacy of HRS-4642 combined with Nimotuzumab in patients with recurrent or metastatic pancreatic ductal adenocarcinoma.
- Trial name
- NCT06773130
- Testing
- HRS-4642, Nimotuzumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.
- Trial name
- M-POP (NCT07905131)
- Testing
- Navlimetostat, mFOLFIRINOX Treatment Regimen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Daniel Nussbaum, M.D.
Pancreas Cancer, Pancreatic Carcinoma
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- FORTIFIDE (NCT06592664)
- Testing
- certepetide, nab-paclitaxel, gemcitabine
- Sponsor
- Lisata Therapeutics, Inc.
Pancreatic Cancer
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
- Trial name
- NCT06941857
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Ductal Adenocarcinoma (PDAC)
"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.
- Trial name
- NCT06044064
- Testing
- A blood sample for CA 19-9 (cancer detection test)
- Volunteers
- 100 people
- Sponsor
- Asian Institute of Gastroenterology, India
Chronic Pancreatitis, PDAC - Pancreatic Ductal Adenocarcinoma
Early Detection of PDAC in Patients With Chronic Pancreatitis
The goal of this study is to find simple warning signs that doctors can use to spot pancreatic cancer early in people who have chronic pancreatitis.
- Trial name
- NCT07104864
- Testing
- histopathological confirmation
- Where
- China
- Volunteers
- 359 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Pancreatic Adenocarcinoma (Ductal Adenocarcinoma), Early Detection of Cancer
Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study
Pancreatic ductal adenocarcinoma (PDAC) is diagnosed at an advanced, incurable stage in more than 80% of cases in Switzerland. Certain warning signs - new-onset diabetes, unexplained weight loss, or a family history of pancreatic…
- Trial name
- PANCATCH-Pilot (NCT07723781)
- Testing
- Structured case-finding pathway (MRI/MRCP + PancreaSure biomarker assay)
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Saskia Hendrich
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
- Conditions
- Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07223047
- Testing
- BMS-986523, Gemcitabine, Nab-Paclitaxel
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 252 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Ductal Adenocarcinoma
Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
This clinical trial is looking at the effect of a new drug called GDC-0449 in patients with cancer of the pancreas. Laboratory studies have shown that this drug blocks a process in pancreatic cells thought to be involved in…
- Trial name
- HIPPoS (NCT01096732)
- Testing
- GDC-0449
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Lisa Bax
PDAC - Pancreatic Ductal Adenocarcinoma
PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- PDAC-PATHWAYS (NCT07047807)
- Testing
- PDAC-PATHWAYS, Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Ductal Adenocarcinoma (mPDAC), Pancreatic Ductal Adenocarcinoma (PDAC)
How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery
Pre-operative biliary drainage (PBD) is a procedure used to relieve bile duct obstruction, a common issue in patients with pancreatic cancer.
- Trial name
- PBDSOO (NCT07444840)
- Testing
- Pre operative biliary drainage
- Volunteers
- 90 people
- Sponsor
- East Lancashire Hospitals NHS Trust